These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36244310)

  • 21. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
    Bowden-Reid E; Ledger S; Zhang Y; Di Giallonardo F; Aggarwal A; Stella AO; Akerman A; Milogiannakis V; Walker G; Rawlinson W; Turville S; Kelleher AD; Ahlenstiel C
    Antiviral Res; 2023 Sep; 217():105677. PubMed ID: 37478918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 nsp13 Restricts Episomal DNA Transcription without Affecting Chromosomal DNA.
    Li A; Zhang B; Zhao K; Yin Z; Teng Y; Zhang L; Xu Z; Liang K; Cheng X; Xia Y
    J Virol; 2023 Jul; 97(7):e0051223. PubMed ID: 37347173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase.
    Zeng J; Weissmann F; Bertolin AP; Posse V; Canal B; Ulferts R; Wu M; Harvey R; Hussain S; Milligan JC; Roustan C; Borg A; McCoy L; Drury LS; Kjaer S; McCauley J; Howell M; Beale R; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2405-2423. PubMed ID: 34198322
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
    J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic developments for SARS-CoV-2 infection-Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice.
    Săndulescu O; Apostolescu CG; Preoțescu LL; Streinu-Cercel A; Săndulescu M
    Front Microbiol; 2023; 14():1132501. PubMed ID: 36937282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
    Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and structural characterization of chicoric acid as a SARS-CoV-2 nucleocapsid protein ligand and RNA binding disruptor.
    Mercaldi GF; Bezerra EHS; Batista FAH; Tonoli CCC; Soprano AS; Shimizu JF; Nagai A; da Silva JC; Filho HVR; do Nascimento Faria J; da Cunha MG; Zeri ACM; Nascimento AFZ; Proenca-Modena JL; Bajgelman MC; Rocco SA; Lopes-de-Oliveira PS; Cordeiro AT; Bruder M; Marques RE; Sforça ML; Franchini KG; Benedetti CE; Figueira ACM; Trivella DBB
    Sci Rep; 2022 Nov; 12(1):18500. PubMed ID: 36323732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
    Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2.
    Hahn F; Häge S; Herrmann A; Wangen C; Kicuntod J; Jungnickl D; Tillmanns J; Müller R; Fraedrich K; Überla K; Kohlhof H; Ensser A; Marschall M
    Pathogens; 2021 Aug; 10(9):. PubMed ID: 34578109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and structural studies of natural inhibitors against SARS-CoV-2 viral RNA methyltransferase (NSP16).
    Kumar M; Roy A; Rawat RS; Alok A; Tetala KKR; Biswas NR; Kaur P; Kumar S
    J Biomol Struct Dyn; 2022; 40(24):13965-13975. PubMed ID: 34766876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins.
    Prentice E; McAuliffe J; Lu X; Subbarao K; Denison MR
    J Virol; 2004 Sep; 78(18):9977-86. PubMed ID: 15331731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
    Zhao J; Zhang G; Zhang Y; Yi D; Li Q; Ma L; Guo S; Li X; Guo F; Lin R; Luu G; Liu Z; Wang Y; Cen S
    Antiviral Res; 2021 Dec; 196():105209. PubMed ID: 34801588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV-2 Repurposing Potential:
    Rabie AM; Abdalla M
    ACS Bio Med Chem Au; 2022 Dec; 2(6):565-585. PubMed ID: 37582236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against
    Naidu SAG; Mustafa G; Clemens RA; Naidu AS
    J Diet Suppl; 2023; 20(2):254-283. PubMed ID: 34850656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease.
    Rabie AM
    ACS Omega; 2022 Jun; 7(25):21385-21396. PubMed ID: 35785294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structure of SARS-CoV-2 nsp10-nsp16 in complex with small molecule inhibitors, SS148 and WZ16.
    Klima M; Khalili Yazdi A; Li F; Chau I; Hajian T; Bolotokova A; Kaniskan HÜ; Han Y; Wang K; Li D; Luo M; Jin J; Boura E; Vedadi M
    Protein Sci; 2022 Sep; 31(9):e4395. PubMed ID: 36040262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Docking Studies to Identify Promising Natural Inhibitors Targeting SARS-CoV-2 Nsp10-Nsp16 Protein Complex.
    Bhardwaj A; Sharma S; Singh SK
    Turk J Pharm Sci; 2022 Feb; 19(1):93-100. PubMed ID: 35227055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral Drug Discovery for the Treatment of COVID-19 Infections.
    Ng TI; Correia I; Seagal J; DeGoey DA; Schrimpf MR; Hardee DJ; Noey EL; Kati WM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0.
    Gervasoni S; Vistoli G; Talarico C; Manelfi C; Beccari AR; Studer G; Tauriello G; Waterhouse AM; Schwede T; Pedretti A
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.